Related references
Note: Only part of the references are listed.Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia
Anne C. Goldberg et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
M. K. Pasanen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice
Cuiping Chen et al.
DRUG METABOLISM AND DISPOSITION (2007)
Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid
Theunis C. Goosen et al.
DRUG METABOLISM AND DISPOSITION (2007)
Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers
Y. Y. Lau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
Pertti J. Neuvonen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport
T Sakaeda et al.
PHARMACEUTICAL RESEARCH (2006)
An open-label, crossover study of the pharmacokinetics of insoluble Drug Delivery (R)-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers
R Penn et al.
CLINICAL THERAPEUTICS (2006)
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro:: Effect of fibrates and rifampicin
LI Kajosaari et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport
M Yamazaki et al.
XENOBIOTICA (2005)
Differential interaction of 3-hydroxy-3-methylglutaryl-COA reductase inhibitors with ABCB1, ABCC2, and OATP1B1
CP Chen et al.
DRUG METABOLISM AND DISPOSITION (2005)
Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans
AJ Bergman et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
DW Schneck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
C Kyrklund et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers
PD Martin et al.
CLINICAL THERAPEUTICS (2003)
Gemfibrozil greatly increases plasma concentrations of cerivastatin
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Effects of fibrates on metabolism of statins in human hepatocytes
T Prueksaritanont et al.
DRUG METABOLISM AND DISPOSITION (2002)
Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization
T Prueksaritanont et al.
DRUG METABOLISM AND DISPOSITION (2002)
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
C Kyrklund et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Atorvastatin transport in the Caco-2 cell model: Contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter
XC Wu et al.
PHARMACEUTICAL RESEARCH (2000)
Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers
WJ Pan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Share Paper
